This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cardiovasculardisease remains a leading cause of morbidity and mortality in adults despite recent scientific advancements. Palliative care for adults with advanced cardiovasculardisease has the potential to significantly improve quality of life for individuals living with cardiovasculardisease and their informal care partners.
Background Menopause is a timely opportunity to screen for cardiovasculardisease (CVD) and intervene with healthier lifestyles. Primary outcome was new-onset CVD (self-reported heart disease/stroke) based on survey data at Wave 2 (2012–2015) and/or Wave 3 (2018–2020).
BackgroundThere is a growing body of evidence indicating that metabolites are associated with an increased risk of cardiovasculardiseases (CVDs), the underlying causality of these associations remains largely unchallenged. After Bonferroni correction, causal associations were found to be significant with p-values less than 0.05.
Care for survivors after an acute attack of COVID-19 should include paying close attention to cardiovascular health and disease.Systematic Review RegistrationPROSPERO [CRD42022353965].
In recent years, the incidence of cardiovasculardisease (CVD) has risen steadily, significantly impacting public health. This review examines the associations between SCH and dyslipidemia, carotid intima-media thickness (C-IMT), cardiac dysfunction, and cardiovascular event risk.
Despite clinical observations of Baduanjin's cardiovascular benefits, systematic evidence for older adults remains limited. Moreover, the effects of Baduanjin exercise on functional capacity in older adults with cardiovasculardiseases have not been adequately investigated. 67, 95% CI: 2.76 to 1.17, p=0.0001, I2=93%).
However, it remains unclear which type of exercise is most effective for managing AS, particularly in individuals at high risk for cardiovasculardiseases (CVD). BackgroundPrevious studies have shown that exercise can improve arterial stiffness (AS).
The purpose of this American Heart Association science advisory is to describe the existing evidence on device-measured sedentary behavior and light-intensity physical activity in relation to cardiovascular health during pregnancy and to make specific calls to action for future research to improve health outcomes and to promote health equity.
Cardiovasculardiseases remain a global health crisis, spurring an urgent demand for innovative diagnostic tools that enable early detection and effective treatment. These cutting-edge advancements promise to enhance patient care and outcomes by providing real-time insights into heart health.
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovasculardisease in patients with cancer and survivors.
BackgroundNarcolepsy is linked to adverse cardiovasculardisease (CVD) outcomes, but few studies have examined its associations with subclinical CVD, including in children. Detection of these outcomes early in the course of narcolepsy could help reduce the burden of adverse cardiovascular events later in life.
The digital determinants of health include the impact of digital technologies (eg, wearables, telemedicine) across health outcomes. Evidence of effective interventions using technology to improve cardiovascular health through positive behavior change is critical for preventing cardiovasculardisease events.
One such syndrome that has been associated with poor outcomes is cognitive frailty: the simultaneous presence of cognitive impairment, without evidence of dementia, and physical frailty, which results in decreased cognitive reserve.
With the global impact of cardiovasculardisease, there is a dire need to understand the mechanisms in the heart during injury and stress. However, epigenetic mechanisms have been shown to regulate functionality across cardiac cells and improve outcomes during stress or injury.
Hospital-based researchers from Denmark have reported a substantial increase in cardiovasculardisease risk among male users of anabolic androgenic steroids (AAS). Long-term health outcomes for AAS users show extreme increases in heart-related health risks.
Despite its known correlations with risk of cardiovasculardisease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening.
Dialysis patients using a more traditional home hemodialysis procedure have lower incidence of cardiovasculardisease than patients using a less invasive peritoneal catheter for dialysis at home, according to a study led by a University of Cincinnati College of Medicine researcher.
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis. Abstract Aims Clonal haematopoiesis (CH) is recognized as a significant risk factor for various non-haematologic conditions, including cardiovasculardiseases.
milla1cf Tue, 03/26/2024 - 13:00 March 26, 2024 — Esperion announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen ) Outcomes subgroup analyses as poster presentations at th e 2024 American College of Cardiology’s Annual Scientific Session ( ACC.24 24 ) in Atlanta, Georgia.
One in five women suffer from hypertension worldwide, and almost half of the mortality in women is caused by cardiovasculardisease (CVD) (WHO). The timely launch of the Women’s Health Strategy for England in 2022 focuses attention on the changing health and needs of women across their life.
Atherosclerosis (ASVD) remains a leading driver of cardiovasculardisease (CVD), a global health challenge that claims millions of lives each year. Precision Medicine: Personalizing Prevention for Better Outcomes Precision medicine provides tools to customize prevention and treatment plans based on individual risk factors.
The beneficial effects of fenofibrate on atherosclerotic cardiovasculardisease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-ca.
Among participants with type 2 diabetes and cardiovasculardisease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
Adverse pregnancy outcomes are common among pregnant individuals and are associated with long-term risk of cardiovasculardisease. Individuals with adverse pregnancy outcomes also have an increased incidence of cardiovasculardisease risk factors after delivery.
Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg muscles may help detect cardiovasculardisease earlier than standardized tests, opening the door to earlier treatment and better outcomes.
Global progress in addressing cardiovasculardiseases (CVD) has been insufficient to attain the nine WHO non-communicable disease (NCD) targets and the Sustainable Development Goal (SDG) target of reducing premature NCD mortality by one-third by 2030. This review examines the reasons for this situation to propose a way forward.
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovasculardiseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.
Cardiovasculardisease (CVD) represents the leading cause of mortality and disability all over the world. Identifying new targeted therapeutic approaches has become a priority of biomedical research to improve patient outcomes and quality of life.
Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovasculardisease risk among women enrolled in the Women’s Health Study.
The atherogenic index of plasma (AIP) is a critical metric for predicting cardiovascularoutcomes. However, its associations with cardiovasculardisease mortality (CVM) and all-cause mortality (ACM) remain unc.
On this state of the art, we summarize the available literature on the effectiveness of virtual reality on various physical and psychological outcomes in patients with atherosclerotic cardiovasculardisease.
AimsHistorically, atherosclerotic cardiovasculardisease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). On the other hand, purified eicosapentaenoic acid (EPA), but not in combination with docosahexaenoic acid (DHA), has produced favourable ASCVD outcomes.
We assessed the association of cannabis use (number of days of cannabis use in the past 30 days) with self‐reported cardiovascularoutcomes (coronary heart disease, myocardial infarction, stroke, and a composite measure of all 3) in multivariable regression models, adjusting for tobacco use and other characteristics in adults 18 to 74 years old.
Implementing patient-centered palliative care therapies, including prescribing, adjusting or discontinuing medications as needed, may help control symptoms and improve quality of life for people with heart disease, according to "Palliative Pharmacotherapy for CardiovascularDisease," a new scientific statement from the American Heart Association, published (..)
Its effects on the heart are particularly alarming, as smoking significantly increases the risk of cardiovasculardiseases (CVDs) and complicates medical procedures such as minimally invasive or bloodless heart surgeries. Impaired Healing and Recovery Nicotine constricts blood vessels, reducing blood flow to surgical sites.
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovasculardisease (ASCVD), chronic kidney disease (CKD), or both.
Outcomes were body mass index, highdensity lipoprotein cholesterol, lowdensity lipoprotein cholesterol, fasting triglycerides, and the presence of hypertension (n=449), diabetes (n=66), metabolic syndrome (n=254), or coronary heart disease (n=25). The primary measure compared MBH with amygdala (MBH/amygdala).
This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovasculardisease.
This scientific statement outlines the current state of the art on the use of artificial intelligence algorithms and data science in the diagnosis, classification, and treatment of cardiovasculardisease.
ObjectiveThis study aimed to evaluate the integration of the Hospital-Community-Home (HCH) model with the Self-Mutual-Group (SMG) health management model for high-risk populations with cardiovasculardisease in the Yuhua community of Shijiazhuang city.
The primary outcome was risk of an ASCVD hospitalization composite outcome (myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, stroke, transient ischemic accident) after COPD hospitalization relative to before COPD hospitalization. P0.0001); for 90 days, 0.69 (95% CI, 0.640.75;P0.0001);
This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. The development of the Tina-quant Lipoprotein (a) Gen.2 J Clin Lipidol. 2024.03.001.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
81 
Let's personalize your content